Selected research
Industry Research
Antibody Drug Conjugates (ADCs) Industry Research Report 2026
Market perspective
The global Antibody Drug Conjugates (ADCs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antibody Drug Conjugates (ADCs) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antibody Drug Conjugates (ADCs) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antibody Drug Conjugates (ADCs) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antibody Drug Conjugates (ADCs) include AbGenomics, ADC Therapeutics, Astellas Pharma, Genmab, Kairos Therapeutics, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and Bayer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antibody Drug Conjugates (ADCs) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antibody Drug Conjugates (ADCs).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody Drug Conjugates (ADCs) Market by Company
AbGenomics
ADC Therapeutics
Astellas Pharma
Genmab
Kairos Therapeutics
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
Bayer
Pfizer
Roche
Novartis
Antibody Drug Conjugates (ADCs) Segment by Type
Seattle Genetics Technology
Immunomedics Technology
ImmunoGen Technology
Antibody Drug Conjugates (ADCs) Segment by Application
Hospital
Clinics
Others
Antibody Drug Conjugates (ADCs) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug Conjugates (ADCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug Conjugates (ADCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug Conjugates (ADCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antibody Drug Conjugates (ADCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Seattle Genetics Technology
- Immunomedics Technology
- ImmunoGen Technology
Applications
- Hospital
- Clinics
- Others
Companies covered
- AbGenomics
- ADC Therapeutics
- Astellas Pharma
- Genmab
- Kairos Therapeutics
- Seattle Genetics
- Takeda Pharmaceuticals
- AbbVie
- Bayer
- Pfizer
- Roche
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antibody Drug Conjugates (ADCs) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Seattle Genetics Technology
- 2.2.3 Immunomedics Technology
- 2.2.4 ImmunoGen Technology
- 2.3 Antibody Drug Conjugates (ADCs) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Antibody Drug Conjugates (ADCs) Breakdown Data by Type
- 3.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2021-2026)
- 3.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2027-2032)
4 Antibody Drug Conjugates (ADCs) Breakdown Data by Application
- 4.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Application (2021-2026)
- 4.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2021-2032)
- 5.2 Global Antibody Drug Conjugates (ADCs) Growth Trends by Region
- 5.2.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antibody Drug Conjugates (ADCs) Historic Market Size by Region (2021-2026)
- 5.2.3 Antibody Drug Conjugates (ADCs) Forecasted Market Size by Region (2027-2032)
- 5.3 Antibody Drug Conjugates (ADCs) Market Dynamics
- 5.3.1 Antibody Drug Conjugates (ADCs) Industry Trends
- 5.3.2 Antibody Drug Conjugates (ADCs) Market Drivers
- 5.3.3 Antibody Drug Conjugates (ADCs) Market Challenges
- 5.3.4 Antibody Drug Conjugates (ADCs) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue
- 6.1.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue (2021-2026)
- 6.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2021-2026)
- 6.2 Global Antibody Drug Conjugates (ADCs) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antibody Drug Conjugates (ADCs) Head Office and Area Served
- 6.4 Global Antibody Drug Conjugates (ADCs) Players, Product Type & Application
- 6.5 Global Antibody Drug Conjugates (ADCs) Manufacturers Established Date
- 6.6 Global Antibody Drug Conjugates (ADCs) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
- 7.2 North America Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 7.4 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
- 8.2 Europe Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 8.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
- 9.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
- 10.2 South America Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 10.4 South America Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
- 11.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AbGenomics
- 12.1.1 AbGenomics Company Information
- 12.1.2 AbGenomics Business Overview
- 12.1.3 AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.1.4 AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.1.5 AbGenomics Recent Developments
- 12.2 ADC Therapeutics
- 12.2.1 ADC Therapeutics Company Information
- 12.2.2 ADC Therapeutics Business Overview
- 12.2.3 ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.2.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.2.5 ADC Therapeutics Recent Developments
- 12.3 Astellas Pharma
- 12.3.1 Astellas Pharma Company Information
- 12.3.2 Astellas Pharma Business Overview
- 12.3.3 Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.3.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.3.5 Astellas Pharma Recent Developments
- 12.4 Genmab
- 12.4.1 Genmab Company Information
- 12.4.2 Genmab Business Overview
- 12.4.3 Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.4.4 Genmab Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.4.5 Genmab Recent Developments
- 12.5 Kairos Therapeutics
- 12.5.1 Kairos Therapeutics Company Information
- 12.5.2 Kairos Therapeutics Business Overview
- 12.5.3 Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.5.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.5.5 Kairos Therapeutics Recent Developments
- 12.6 Seattle Genetics
- 12.6.1 Seattle Genetics Company Information
- 12.6.2 Seattle Genetics Business Overview
- 12.6.3 Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.6.5 Seattle Genetics Recent Developments
- 12.7 Takeda Pharmaceuticals
- 12.7.1 Takeda Pharmaceuticals Company Information
- 12.7.2 Takeda Pharmaceuticals Business Overview
- 12.7.3 Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.7.5 Takeda Pharmaceuticals Recent Developments
- 12.8 AbbVie
- 12.8.1 AbbVie Company Information
- 12.8.2 AbbVie Business Overview
- 12.8.3 AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.8.4 AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.8.5 AbbVie Recent Developments
- 12.9 Bayer
- 12.9.1 Bayer Company Information
- 12.9.2 Bayer Business Overview
- 12.9.3 Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.9.4 Bayer Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.9.5 Bayer Recent Developments
- 12.10 Pfizer
- 12.10.1 Pfizer Company Information
- 12.10.2 Pfizer Business Overview
- 12.10.3 Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.10.4 Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.10.5 Pfizer Recent Developments
- 12.11 Roche
- 12.11.1 Roche Company Information
- 12.11.2 Roche Business Overview
- 12.11.3 Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.11.4 Roche Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.11.5 Roche Recent Developments
- 12.12 Novartis
- 12.12.1 Novartis Company Information
- 12.12.2 Novartis Business Overview
- 12.12.3 Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2021-2026)
- 12.12.4 Novartis Antibody Drug Conjugates (ADCs) Product Portfolio
- 12.12.5 Novartis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst